Organization
Netherlands Cancer Institute (Netherlands)
2 abstracts
Abstract
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute (Netherlands), Hartwig Medical Foundation, Erasmus Medical Cancer Institute, Department of Biometrics,
Abstract
Cell-free DNA fragmentation profiling for therapeutic response monitoring in metastatic colorectal cancer.Org: Delfi Diagnostics, Inc., Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Netherlands Cancer Institute (Netherlands), The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, Fred Hutchinson Cancer Center, Seattle, WA, Virginia Oncology Associates, Hampton, VA, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, Allegheny Health Network Cancer Institute, Pittsburgh, PA, University of California San Diego, La Jolla, CA, Dana-Farber Cancer Institute, Boston, MA, Indiana University Health Arnett Cancer Center, Lafayette, IN, University at Buffalo, Buffalo, NY, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Oregon Health and Science University Knight Cancer Institute, Portland, OR, University of Chicago, Chicago, IL, The Johns Hopkins University School of Medicine,